The estimated Net Worth of Frank Verwiel is at least $626 Tisíc dollars as of 17 June 2024. Frank Verwiel owns over 1,505 units of Intellia Therapeutics Inc stock worth over $363,268 and over the last 9 years he sold NTLA stock worth over $37,625. In addition, he makes $225,497 as Independent Chairman of the Board at Intellia Therapeutics Inc.
Frank has made over 1 trades of the Intellia Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 1,505 units of NTLA stock worth $37,625 on 17 June 2024.
The largest trade he's ever made was selling 1,505 units of Intellia Therapeutics Inc stock on 17 June 2024 worth over $37,625. On average, Frank trades about 75 units every 0 days since 2015. As of 17 June 2024 he still owns at least 17,948 units of Intellia Therapeutics Inc stock.
You can see the complete history of Frank Verwiel stock trades at the bottom of the page.
Dr. Frank A. G. M. Verwiel M.D. serves as Independent Chairman of the Board of the Company. He brings more than 25 years of strategic, operational and international experience in the biotech and pharmaceutical industry to Intellia’s board of directors as its chairman. Frank also currently serves as chairman of the board of directors of ObsEva SA, a biopharmaceutical company focused on women’s reproductive health, and holds membership on the board of Bavarian Nordic A/S (CPH: BAVA). Previously, he served on the board of directors of AveXis Inc. (NASDAQ: AVXS) until the acquisition by Novartis (2018) and Achillion Pharmaceuticals (NASDAQ: ACHN) until the acquisition by Alexion (2020), Inc. He was also a member of the board of the Biotechnology Innovation Organization. Frank possesses significant biotech and pharmaceutical experience, having been the president and chief executive officer of Aptalis Pharma Inc., prior to its acquisition in 2014 by Forest Laboratories. Additionally, Frank led the global hypertension franchise at Merck & Co., served as managing director of Merck’s Dutch subsidiary, and held numerous leadership positions in the commercial organization at Servier Laboratories. Frank received an M.D. from Erasmus University in Rotterdam, Netherlands. He received his MBA from the Institut Européen d’Administration des Affaires (INSEAD) in Fontainebleau, France.
As the Independent Chairman of the Board of Intellia Therapeutics Inc, the total compensation of Frank Verwiel at Intellia Therapeutics Inc is $225,497. There are 13 executives at Intellia Therapeutics Inc getting paid more, with Laura Sepp-Lorenzino having the highest compensation of $1,762,490.
Frank Verwiel is 58, he's been the Independent Chairman of the Board of Intellia Therapeutics Inc since 2020. There are 8 older and 11 younger executives at Intellia Therapeutics Inc. The oldest executive at Intellia Therapeutics Inc is Jesse Goodman, 68, who is the Independent Director.
Frank's mailing address filed with the SEC is C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE, MA, 02139.
Over the last 9 years, insiders at Intellia Therapeutics Inc have traded over $210,567,884 worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth $23,117,886 . The most active insiders traders include Carl L Gordon, Jean Francois Formela a Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,357,638. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth $9,287.
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Intellia Therapeutics Inc executives and other stock owners filed with the SEC include: